Oasmia intends to delist from NASDAQ in the US to reduce complexity and costs

NEXT STORY
AB Science today reports the analysis for its phase 3 trial evaluating masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma
PREV STORY
Hemodialysis Equipment Market is Expected to Rise at 4.5% CAGR, Increasing Prevalence of Chronic Kidney Disorders Likely to Support Expansion: Fortune Business Insights
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Celularity to Present at H.C. Wainwright Global Life Sciences Conference

author_avatar
NASDAQ Market News

Keryx Biopharmaceuticals Announces Publication of Auryxia® (ferric citrate) Phase 3 Trial Results for Iron Deficiency Anemia (IDA) in Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) in Journal of the American Society of Nephrology

BOSTON, Jan. 12, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company ...

author_avatar
NASDAQ Market News

Salarius Pharmaceuticals Adds Memorial Sloan Kettering Cancer Center and Nationwide Children’s Hospital as Clinical Sites for Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma

author_avatar
NASDAQ Market News